Adf Foods Ltd has informed BSE regarding the details of Voting results of Postal Ballot, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here

On BSE's website, it is mentioned that BSE has sought clarification from the company with respect to news article appearing on hindi.moneycontrol.com - July 12, 2018 titled "Drug Controller''s Action on Ajanta Pharma". However, we have not received any letter/e-mail from BSE in this regard. Nonetheless, we are giving below the clarification on the news item, which we have submitted to NSE: 1. There is no action against Ajanta Pharma Ltd. from the office of Drug Controller General of India and we refute the allegations made against the company in the said article. 2. The action is taken against M/s. Safetab Life Sciences, who is the manufacturer of drugs. We are only marketing the drugs. 3. There is no impact of this article on the Company as Ajanta Pharma Ltd. is fully compliant with all the applicable regulatory requirements. 4. Since this would have no bearing on the performance or operations of the Company, the same is not required to be disclosed under Regulation 30 of the Listing Regulations, hence not disclosed. We hope above clarifies the position.

With reference to SEBI, circular No: SEBI/HO/MIRSD/DOP1/CIR/P/2018/73 dated April 20, 2018, has mandated all listed Companies to update the Permanent Account Number (PAN) and Bank account details of the shareholders. A letter communication was sent to the shareholders as enclosed. Kindly take the same on record.

Sub : Resignation of Dr. Panna Akhani as an Independent Director In terms of Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 we hereby inform you that the company has received the resignation of Dr. Panna Akhani designated as an Independent Director of the company due to the personal reasons on 16th July 2018. This is for your information and record purposes.

Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015, we would like to inform you that Mr. Hrushikesh S. Kulkarni, Chartered Accountant (Membership No.160187), Independent Auditor of the Company, who was appointed for a period of five years to hold office from the conclusion of 8th Annual General Meeting (AGM) untill the conclusion of 13th AGM has informed, vide his letter dated July 16, 2018, his inability to continue as Independent Auditor of the Company due to challenges in retaining required manpower, particularly in the light of the implementation of Ind-AS framework with effect from April 1, 2018, thereby putting constraints in meeting stringent timelines, with effect from the conclusion of ensuing 9th AGM of the Members of the Company. We request you to kindly take the above information on record.

The Company has allotted today, 62,764 equity shares of Rs.10/- each to the employees of the Company who have exercised options under various Stock Option Plans. The said shares shall rank pari-passu with the existing equity shares of the Company in all respects.

Press Release - Blue Star wins prestigious Engineering Facility Management (EFM) orders from Airport and Metro segments

Zydus receives final approval from the USFDA for Clindamycin Phosphate Topical Solution USP

Inter alia, the Board of Directors has also approved the payment of Second Interim dividend of Rs. 6 per equity share of face value of Re 1 each, for the financial year ending December 31, 2018, which will be paid on August 7, 2018. The company has informed that after serving for a decade, Dr. Nachiket Mor will be completing his tenure as Independent Director of CRISIL on July 23, 2018 and will cease to be a Director on CRISIL s Board post this date.

Kindly be informed that the Board of Directors of the Company, at their meeting held today, has approved the Unaudited Standalone and Consolidated Financial Results for the second quarter ended June 30, 2018. A copy of the Unaudited Financial Results of the Company, along with a copy of the Limited Review Report and the Press Release in this regard are enclosed. The Board of Directors has also approved the payment of Second Interim dividend of Rs. 6 per equity share of face value of Re 1 each, for the financial year ending December 31, 2018, which will be paid on August 7, 2018. We also wish to inform you that after serving for a decade, Dr. Nachiket Mor will be completing his tenure as Independent Director of CRISIL on July 23, 2018 and will cease to be a Director on CRISIL's Board post this date. The meeting of the Board of Directors commenced at 9.30 a.m. IST and concluded at 5.45 p.m. IST today. Kindly take this communication on record and inform your members accordingly.

Appointment of Company Secretary Ms. Anita Lalwani, Member of Institute of Company Secretaries of India as Company Secretary cum Compliance Officer of the Company.

Axis Capital Ltd. ("Manager to Buyback Offer") has submitted to BSE a copy of Draft Letter of Offer for the attention of the Holders/Beneficial Owners of Equity Shares of D. B. Corp Ltd ("Target Company") for Buyback of Equity Shares through Tender Offer.

Symbol DCMSHRIRAMCompany DCM Shriram LimitedIndustry -Broadcast Date/Time 17-Jul-2018 16:35Subject Daily Buy-Back of equity sharesAnnouncement DCM Shriram Limited has informed the Exchange regarding daily report pursuant to Regulation 15(i) of the Buyback Regulations regarding the equity shares bought-back on July 17, 2018. Total no. of equity shares bought back are 168144

We, hereby intimate that the company in its Board Meeting Held on 16.07.2018, accepted the resignation tendered by Mrs. Anjul Agarwal from the post of Independent Director of the Company with effect from 15.06.2018. Copy of Board Resolution is enclosed hereby.

Ellora Paper Mills Ltd has informed BSE about Outcome of Board Meeting held on July 17, 2018.

We wish to inform you that the Company has allotted 14,86,314 Equity shares of Rs. 10/- each bearing distinctive numbers 688,502,478 to 689,988,791 on 17th July 2018, under Employee Stock Option Scheme 2003 of the Company. Consequent to the said allotment, the paid up capital of the Company has increased to Rs. 6,899,887,910 consisting of 689,988,791 Equity shares of Rs. 10/- each. We request you to take the above intimation on record, which has been made to you pursuant to Regulation 30 and Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. Thanks & Regards, Compliance Officer

Inter alia, to discuss and approve on the following issues. 1. Appointment .of Mrs. Kolla Sudha (DIN Number 06603646) as lndependent Director of the Company. 2. Accepted Resignation of Director Mr. V.Poorna Chandar Rao. 3. Authorizations to appear before BSE 4. Any other matter as may be permitted by the chair

The Compensation Committee at its meeting held on July 17, 2018 has approved the allotment of 22,300 equity shares of face value of Rs. 5.00 each pursuant to the exercise of the stock options by the eligible employees of the company under the Genesys ESOP Scheme -2010. Consequently, post-allotment the paid-up capital of the company shall stand increased to Rs. 15,48,59,060 divided into 3,09,71,812 Equity Shares of face value of Rs. 5.00 each. These shares shall rank pari passu with the existing equity shares of the Company in all respects. You are requested to take the above on your record.

Sub: Glenmark Pharmaceuticals receives ANDA approval for Colesevelam Hydrochloride for Oral Suspension, 1.875 grams/Packet and 3.75 grams/Packet.

Members are hereby informed that Mrs. Urmi Bose and Mr. Mahavir Prasad Saraswat have been appointed as Additional Directors, (Independent) of the Company with effect from 16th July 2018 and will hold the office till conclusion of next Annual General Meeting. Further, Mrs. Amrita Baid and Mr. Amitabh Shukla have resigned from the Board and Board has accepted their resignation. Please note that both Directors who have been appointed by the Company are not debarred from holding the office of director by virtue of any SEBI order or any other such authority. Brief Profile of both the Directors have been provided in the attachment